Journal
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
Volume 407, Issue 24, Pages 7503-7509Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00216-015-8923-8
Keywords
Raman; SERS; Breast cancer; Serum; Nanoparticles; Diagnosis
Ask authors/readers for more resources
In this contribution, we investigated whether surface-enhanced Raman scattering (SERS) of serum can be a candidate method for detecting luminal A breast cancer (BC) at different stages. We selected three groups of participants aged over 50 years: 20 healthy women, 20 women with early localized small BC, and 20 women affected by BC with lymph node involvement. SERS revealed clear spectral differences between these three groups. A predictive model using principal component analysis (PCA) and linear discriminant analysis (LDA) was developed based on spectral data, and its performance was estimated with cross-validation. PCA-LDA of SERS spectra could distinguish healthy from BC subjects (sensitivity, 92 %; specificity, 85 %), as well as subjects with BC at different stages, with a promising diagnostic performance (sensitivity and specificity, a parts per thousand yen80 %; overall accuracy, 84 %). Our data suggest that SERS spectroscopy of serum, combined with multivariate data analysis, represents a minimally invasive, easy to use, and fast approach to discriminate healthy from BC subjects and even to distinguish BC at different clinical stages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available